id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-P-0589-0006,FDA,FDA-2009-P-0589,Laser Pharmaceuticals LLC to FDA - Letter,Other,Letter(s),2011-06-20T04:00:00Z,2011,6,,,2013-08-11T01:41:52Z,,0,0,0900006480e32b4a
FDA-2009-P-0589-0007,FDA,FDA-2009-P-0589,"JAYMAC Pharmaceuticals, LLC to FDA - Letter",Other,Letter(s),2011-06-20T04:00:00Z,2011,6,,,2013-07-27T23:54:56Z,,0,0,0900006480e3a860
FDA-2009-P-0589-0005,FDA,FDA-2009-P-0589,Buchanan Ingersoll & Rooney PC to FDA/CDER - Letter,Other,LET-Letter,2011-03-04T05:00:00Z,2011,3,2011-03-04T05:00:00Z,,2013-08-11T01:40:15Z,,0,0,0900006480bfe64c
FDA-2009-P-0589-0004,FDA,FDA-2009-P-0589,"FDA/CDER Interim Response to Buchanan Ingersoll & Rooney PC, March 2, 2011 - Letter",Other,LET-Letter,2011-03-02T05:00:00Z,2011,3,2011-03-02T05:00:00Z,,2011-03-02T22:41:06Z,,0,0,0900006480bfd977